What is Accentia Biopharmaceuticals?
Dr. O’Donnell: Accentia is a biopharmaceutical company focused on late- stage product opportunities in the respiratory and oncology marketplaces. We are a commercial-stage enterprise with products currently available to the public. We think Accentia has an attractive business and investment model. The company has the favorable risk profile of a specialty pharmaceutical company, without the limited upside in the pipeline that is characteristic of the traditional specialty pharmaceutical business model. In particular, we have two late-stage potential blockbuster products now in clinical testing. Each is an example of a targeted therapeutic. Both of these products appear to have an enhanced safety profile and, at the same time, significantly improved efficacy. We feel the upside for these products is extremely exciting. In regard to our business model, when we started assembling what became Accentia about three and a half years ago, we felt there was a largely untapped opportunity to part
